Elicio reports 99% T cell response rate in Phase 2 AMPLIFY-7P trial of ELI-002 7P

Elicio Therapeutics, Inc.

ELI-002 7P induced mKRAS-specific T cell responses in 99% of evaluable patients (89 of 90).
Average fold increase 145.3x over baseline; median 44.3x; 80% of patients above 9.5x threshold correlated with clinical activity in Phase 1.
85% of patients had combined CD4+CD8 T cell response vs 75% in Phase 1; 67.4% responded to all 7 mKRAS antigens vs 50%.
IDMC recommended continue without modifications after interim safety/efficacy review; company remains blinded to clinical outcomes.
Final disease-free survival analysis anticipated in Q4 2025; Phase 2 includes both MRD+ and MRD- patients.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.